Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home Article of the Week Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol

Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol

ARTICLE: Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol

AUTHORS: Tarek HarbEfthymios Ziogos, Michael Schär, Todd T Brown, Shenghan Lai, Gary GerstenblithAllison G HaysThorsten M Leucker

JOURNAL: Circ Cardiovasc Imaging. 2023 Oct;16(10):e015693. doi: 10.1161/CIRCIMAGING.123.015693.

Coronary endothelial dysfunction is an established driver for the development of coronary atherosclerosis, and abnormal coronary endothelial function (CEF) is an independent predictor of adverse cardiovascular events. Advances in magnetic resonance imaging make it possible to quantify CEF by measuring changes in the coronary cross-sectional area in response to isometric handgrip exercise, an endothelial-dependent stressor. Healthy coronaries respond by vasodilatation and thus an increase in cross-sectional area is measured; no change or paradoxical vasoconstriction is seen in the presence of endothelial dysfunction.1 This noninvasive method allows assessment of the effectiveness of interventions that may improve CEF.

For the full article, click here.

nv-author-image

Kelsey Bennett